Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Therapy Platform for Advanced Pancreatic Cancer
NCT06547736Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Oct 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102, garetatug rezetecan, trastuzumab rezetecan, HRS-4642 in pancreatic cancer (PC), sponsored by Fudan University. Started Oct 2024; status: recruiting.
02
Drugs
SHR-A2102garetatug rezetecantrastuzumab rezetecanHRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06547736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547736.